PART I Item 1. B usiness Overview We are a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through discovery and development of novel live biotherapeutic product, or LBP, candidates. We led the successful development and approval of VOWST, the first FDA-approved orally administered microbiome biotherapeutic and a Breakthrough Therapy designated drug, which was sold to Socit des Produits Nestl S.A., or SPN, and with certain of its affiliates, colle...
Q2 FY2026 — expected 2026-08-18
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-12 | 2025-12-31 | 0001193125-26-103276 | EDGAR | 108K words |
| 2025-03-13 | 2024-12-31 | 0000950170-25-038427 | EDGAR | — |
| 2024-03-05 | 2023-12-31 | 0000950170-24-025464 | EDGAR | — |
| 2023-03-07 | 2022-12-31 | 0000950170-23-006374 | EDGAR | — |
| 2022-03-01 | 2021-12-31 | 0000950170-22-002435 | EDGAR | — |
| 2021-03-02 | 2020-12-31 | 0001564590-21-010057 | EDGAR | — |
| 2020-03-02 | 2019-12-31 | 0001564590-20-008002 | EDGAR | — |
| 2019-03-06 | 2018-12-31 | 0001564590-19-006423 | EDGAR | — |
| 2018-03-08 | 2017-12-31 | 0001564590-18-004830 | EDGAR | — |
| 2017-03-16 | 2016-12-31 | 0001564590-17-004551 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-05 | 2026-06-30 | 0001193125-26-334174 | EDGAR | — |
| 2025-11-05 | 2025-09-30 | 0001193125-25-266011 | EDGAR | 67K words |
| 2025-08-06 | 2025-06-30 | 0000950170-25-103611 | EDGAR | — |
| 2025-05-07 | 2025-03-31 | 0000950170-25-065173 | EDGAR | — |
| 2024-11-13 | 2024-09-30 | 0000950170-24-126018 | EDGAR | — |
| 2024-08-13 | 2024-06-30 | 0000950170-24-095821 | EDGAR | — |
| 2024-05-08 | 2024-03-31 | 0000950170-24-055159 | EDGAR | — |
| 2023-11-02 | 2023-09-30 | 0000950170-23-057805 | EDGAR | — |
| 2023-08-08 | 2023-06-30 | 0000950170-23-039439 | EDGAR | — |
| 2023-05-09 | 2023-03-31 | 0000950170-23-019222 | EDGAR | — |
| 2022-11-02 | 2022-09-30 | 0000950170-22-021018 | EDGAR | — |
| 2022-08-03 | 2022-06-30 | 0000950170-22-014052 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-05 | 0001193125-26-333820 | EDGAR | — |
| 2026-08-04 | 0001193125-26-332742 | EDGAR | — |
| 2026-03-16 | 0001193125-26-108482 | EDGAR | 1K words |
| 2026-03-12 | 0001193125-26-103034 | EDGAR | — |
| 2026-03-02 | 0001193125-26-085368 | EDGAR | — |
| 2025-11-05 | 0001193125-25-265708 | EDGAR | — |
| 2025-10-03 | 0001193125-25-230118 | EDGAR | — |
| 2025-08-06 | 0001193125-25-173985 | EDGAR | — |
| 2025-07-22 | 0001193125-25-162552 | EDGAR | — |
| 2025-05-07 | 0001193125-25-114430 | EDGAR | — |
185 total filings indexed. 153 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001609809 |
| Ticker | MCRB |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.serestherapeutics.com |
| Listed | 2015-06-26 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/MCRB (~200 tokens, structured JSON with cryptographic provenance)